As of the latest Form 4 filed Jul 2, 2026.
What Rhythm Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for RYTM.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Garfield Alastair Chief Scientific Officer | FTax | −2.15K | $110.41 | $237K | No | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Garfield Alastair, Chief Scientific Officer | MExercise | +4.45K | — | — | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | JEAN CHRISTOPHE Director | MExercise | +4.71K | — | — | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | MCGIRR DAVID W J Director | MExercise | +4.71K | — | — | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | TETRAULT LYNN A. Director | MExercise | +4.71K | — | — | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Arbuckle Stuart A Director | MExercise | +4.71K | — | — | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | GOOD JENNIFER L Director | MExercise | +4.71K | — | — | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | TETRAULT LYNN A. Director | SSale | −37.0K | $100.32 | $3.71M | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | TETRAULT LYNN A., Director | MExercise | +37.0K | $28.27 | $1.05M | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Smith Hunter C Chief Financial Officer | MExercise | +3.00K | $17.87 | $53.6K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-12 | Smith Hunter C Chief Financial Officer | SSale | −100.00 | $100.10 | $10.0K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-12 | Smith Hunter C, Chief Financial Officer | SSale | −800.00 | $98.99 | $79.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-12 | Smith Hunter C, Chief Financial Officer | SSale | −400.00 | $97.67 | $39.1K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-12 | Smith Hunter C, Chief Financial Officer | SSale | −292.00 | $96.26 | $28.1K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-11 | Smith Hunter C, Chief Financial Officer | SSale | −100.00 | $100.85 | $10.1K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-11 | Smith Hunter C, Chief Financial Officer | SSale | −400.00 | $99.44 | $39.8K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-11 | Smith Hunter C, Chief Financial Officer | SSale | −2.27K | $98.37 | $223K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Hunter C, Chief Financial Officer | SSale | −100.00 | $104.76 | $10.5K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Hunter C, Chief Financial Officer | SSale | −700.00 | $103.68 | $72.6K | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Hunter C, Chief Financial Officer | SSale | −1.91K | $102.66 | $196K | Yes (planned) | Form 4 ↗ |
| 2026-02-06 | 2026-02-05 | Smith Hunter C Chief Financial Officer | SSale | −3.38K | $106.06 | $359K | Yes (planned) | Form 4 ↗ |
| 2026-02-06 | 2026-02-04 | Smith Hunter C, Chief Financial Officer | SSale | −747.00 | $107.67 | $80.4K | Yes (planned) | Form 4 ↗ |
| 2026-02-06 | 2026-02-04 | Smith Hunter C, Chief Financial Officer | SSale | −1.00K | $106.60 | $107K | Yes (planned) | Form 4 ↗ |
| 2026-02-06 | 2026-02-04 | Smith Hunter C, Chief Financial Officer | SSale | −1.50K | $104.74 | $157K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also RYTM’s full analysis or the market-wide insider trading feed. The tabs above jump to RYTM’s other SEC data.
Source: SEC Form 4 filings for RYTM, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.